跳至主要内容
临床试验/CTRI/2010/091/000043
CTRI/2010/091/000043已完成3 期

Evaluation of efficacy and safety of armodafinil versus Modafinil in the treatment of patients with excessive daytime sleepiness associated with narcolepsy: a randomized, open label, comparative, multi-centre trial.

Sun Pharmaceutical Industries Ltd.0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Male or female patients aged between 18 and 65 years.
  • 2. Patients diagnosed with excessive sleepiness associated with narcolepsy.
  • 3. Patient willing to give their informed consent.

排除标准

  • 1. Pregnant or lactating women and women of childbearing potential who are not on acceptable birth control methods.
  • 2. Women using steroidal contraceptives.
  • 3. Patients who have probable diagnosis of a current sleep disorder other than narcolepsy in opinion of the investigator.
  • 4. Patients having any significant uncontrolled medical or psychiatric disorder, other than narcolepsy, that can cause excessive sleepiness.
  • 5. Patients consuming > 600 mg/day of caffeine.
  • 6. Patients having history of alcohol, narcotic or drug abuse.
  • 7. Patients using any of the drugs such as sodium oxybate, lithium, St. John's Wort, methylphenidate, amphetamines, pemoline, antipsychotics, benzodiazepines, zolpidem, zopiclone, MAO inhibitors, anticoagulants, anticonvulsants.
  • 8. Patients with severe renal and hepatic impairment.
  • 9. Patients with known hypersensitivity to armodafinil and modafinil or its inactive ingredients.
  • 10. Has a serum creatinine of > 1.5 x upper limit of normal.
  • 11. Has thyroid stimulating hormone value outside the normal range.
  • 12. Patients having risk of cardiovascular events.
  • 13. Patients having participated in another clinical trial in proceeding one month period.

研究者

相似试验